Global and United States Retinal Biosimilars Market Report & Forecast 2023-2028

Report ID: 1844552 | Published Date: Jan 2025 | No. of Page: 99 | Base Year: 2024 | Rating: 4.8 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Retinal Biosimilars Revenue in Retinal Biosimilars Business (2017-2022) & (US$ Million) Introduction
    1.2 Global Retinal Biosimilars Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Retinal Biosimilars Market Size for the Year 2017-2028
        1.2.2 Global Retinal Biosimilars Market Size for the Year 2017-2028
    1.3 Retinal Biosimilars Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.3.1 The Market Share of United States Retinal Biosimilars in Global, 2017 VS 2022 VS 2028
        1.3.2 The Growth Rate of Retinal Biosimilars Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.4 Retinal Biosimilars Market Dynamics
        1.4.1 Retinal Biosimilars Industry Trends
        1.4.2 Retinal Biosimilars Market Drivers
        1.4.3 Retinal Biosimilars Market Challenges
        1.4.4 Retinal Biosimilars Market Restraints
    1.5 Study Objectives
    1.6 Years Considered
2 Retinal Biosimilars by Type
    2.1 Retinal Biosimilars Market Segment by Type
        2.1.1 Macular Degeneration Drugs
        2.1.2 Diabetic Eye Disease Drugs
        2.1.3 Macular Pucker Drugs
        2.1.4 Others
    2.2 Global Retinal Biosimilars Market Size by Type (2017, 2022 & 2028)
    2.3 Global Retinal Biosimilars Market Size by Type (2017-2028)
    2.4 United States Retinal Biosimilars Market Size by Type (2017, 2022 & 2028)
    2.5 United States Retinal Biosimilars Market Size by Type (2017-2028)
3 Retinal Biosimilars by Application
    3.1 Retinal Biosimilars Market Segment by Application
        3.1.1 Hospital Pharmacies
        3.1.2 Retail Pharmacies
        3.1.3 Online Pharmacies
    3.2 Global Retinal Biosimilars Market Size by Application (2017, 2022 & 2028)
    3.3 Global Retinal Biosimilars Market Size by Application (2017-2028)
    3.4 United States Retinal Biosimilars Market Size by Application (2017, 2022 & 2028)
    3.5 United States Retinal Biosimilars Market Size by Application (2017-2028)
4 Global Retinal Biosimilars Competitor Landscape by Company
    4.1 Global Retinal Biosimilars Market Size by Company
        4.1.1 Top Global Retinal Biosimilars Companies Ranked by Revenue (2021)
        4.1.2 Global Retinal Biosimilars Revenue by Player (2017-2022)
    4.2 Global Retinal Biosimilars Concentration Ratio (CR)
        4.2.1 Retinal Biosimilars Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Companies of Retinal Biosimilars in 2021
        4.2.3 Global Retinal Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Retinal Biosimilars Headquarters, Revenue in Retinal Biosimilars Business (2017-2022) & (US$ Million) Type
        4.3.1 Global Retinal Biosimilars Headquarters and Area Served
        4.3.2 Global Retinal Biosimilars Companies Revenue in Retinal Biosimilars Business (2017-2022) & (US$ Million) Type
        4.3.3 Date of International Companies Enter into Retinal Biosimilars Market
    4.4 Companies Mergers & Acquisitions, Expansion Plans
    4.5 United States Retinal Biosimilars Market Size by Company
        4.5.1 Top Retinal Biosimilars Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Retinal Biosimilars Revenue by Players (2020, 2021 & 2022)
5 Global Retinal Biosimilars Market Size by Region
    5.1 Global Retinal Biosimilars Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Retinal Biosimilars Market Size by Region (2017-2028)
        5.2.1 Global Retinal Biosimilars Market Size by Region: 2017-2022
        5.2.2 Global Retinal Biosimilars Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Retinal Biosimilars Market Size YoY Growth 2017-2028
        6.1.2 North America Retinal Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 U.S.
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Retinal Biosimilars Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Retinal Biosimilars Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
        6.2.12 Philippines
    6.3 Europe
        6.3.1 Europe Retinal Biosimilars Market Size YoY Growth 2017-2028
        6.3.2 Europe Retinal Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Retinal Biosimilars Market Size YoY Growth 2017-2028
        6.4.2 Latin America Retinal Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Retinal Biosimilars Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Retinal Biosimilars Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 U.A.E
7 Company Profiles
    7.1 Novartis (Sandoz)
        7.1.1 Novartis (Sandoz) Company Details
        7.1.2 Novartis (Sandoz) Business Overview
        7.1.3 Novartis (Sandoz) Retinal Biosimilars Introduction
        7.1.4 Novartis (Sandoz) Revenue in Retinal Biosimilars Business (2017-2022)
        7.1.5 Novartis (Sandoz) Recent Development
    7.2 Takeda
        7.2.1 Takeda Company Details
        7.2.2 Takeda Business Overview
        7.2.3 Takeda Retinal Biosimilars Introduction
        7.2.4 Takeda Revenue in Retinal Biosimilars Business (2017-2022)
        7.2.5 Takeda Recent Development
    7.3 Bayer
        7.3.1 Bayer Company Details
        7.3.2 Bayer Business Overview
        7.3.3 Bayer Retinal Biosimilars Introduction
        7.3.4 Bayer Revenue in Retinal Biosimilars Business (2017-2022)
        7.3.5 Bayer Recent Development
    7.4 Genentech
        7.4.1 Genentech Company Details
        7.4.2 Genentech Business Overview
        7.4.3 Genentech Retinal Biosimilars Introduction
        7.4.4 Genentech Revenue in Retinal Biosimilars Business (2017-2022)
        7.4.5 Genentech Recent Development
    7.5 Pfenex
        7.5.1 Pfenex Company Details
        7.5.2 Pfenex Business Overview
        7.5.3 Pfenex Retinal Biosimilars Introduction
        7.5.4 Pfenex Revenue in Retinal Biosimilars Business (2017-2022)
        7.5.5 Pfenex Recent Development
    7.6 Reliance Life Sciences
        7.6.1 Reliance Life Sciences Company Details
        7.6.2 Reliance Life Sciences Business Overview
        7.6.3 Reliance Life Sciences Retinal Biosimilars Introduction
        7.6.4 Reliance Life Sciences Revenue in Retinal Biosimilars Business (2017-2022)
        7.6.5 Reliance Life Sciences Recent Development
    7.7 Hetero Drugs
        7.7.1 Hetero Drugs Company Details
        7.7.2 Hetero Drugs Business Overview
        7.7.3 Hetero Drugs Retinal Biosimilars Introduction
        7.7.4 Hetero Drugs Revenue in Retinal Biosimilars Business (2017-2022)
        7.7.5 Hetero Drugs Recent Development
    7.8 Intas Pharmaceuticals
        7.8.1 Intas Pharmaceuticals Company Details
        7.8.2 Intas Pharmaceuticals Business Overview
        7.8.3 Intas Pharmaceuticals Retinal Biosimilars Introduction
        7.8.4 Intas Pharmaceuticals Revenue in Retinal Biosimilars Business (2017-2022)
        7.8.5 Intas Pharmaceuticals Recent Development
    7.9 Santo Holding
        7.9.1 Santo Holding Company Details
        7.9.2 Santo Holding Business Overview
        7.9.3 Santo Holding Retinal Biosimilars Introduction
        7.9.4 Santo Holding Revenue in Retinal Biosimilars Business (2017-2022)
        7.9.5 Santo Holding Recent Development
    7.10 Regeneron Pharmaceuticals
        7.10.1 Regeneron Pharmaceuticals Company Details
        7.10.2 Regeneron Pharmaceuticals Business Overview
        7.10.3 Regeneron Pharmaceuticals Retinal Biosimilars Introduction
        7.10.4 Regeneron Pharmaceuticals Revenue in Retinal Biosimilars Business (2017-2022)
        7.10.5 Regeneron Pharmaceuticals Recent Development
8 Research Findings and Conclusion
9 Appendix
    9.1 Research Methodology
        9.1.1 Methodology/Research Approach
        9.1.2 Data Source
    9.2 Author Details
    9.3 Disclaimer

List of Tables
    Table 1. Retinal Biosimilars Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Retinal Biosimilars Market Trends
    Table 3. Retinal Biosimilars Market Drivers
    Table 4. Retinal Biosimilars Market Challenges
    Table 5. Retinal Biosimilars Market Restraints
    Table 6. Global Retinal Biosimilars Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Retinal Biosimilars Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Retinal Biosimilars Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Retinal Biosimilars Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Retinal Biosimilars Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Retinal Biosimilars Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Retinal Biosimilars Revenue Share by Player, 2017-2022
    Table 13. Global Retinal Biosimilars Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Retinal Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Retinal Biosimilars as of 2021)
    Table 15. Top Players of Retinal Biosimilars in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Retinal Biosimilars Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Retinal Biosimilars Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Retinal Biosimilars Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Retinal Biosimilars Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Retinal Biosimilars Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Retinal Biosimilars Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Retinal Biosimilars Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Retinal Biosimilars Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Retinal Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Retinal Biosimilars Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Retinal Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Retinal Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Retinal Biosimilars Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Novartis (Sandoz) Company Details
    Table 31. Novartis (Sandoz) Business Overview
    Table 32. Novartis (Sandoz) Retinal Biosimilars Product
    Table 33. Novartis (Sandoz) Revenue in Retinal Biosimilars Business (2017-2022) & (US$ Million)
    Table 34. Novartis (Sandoz) Recent Development
    Table 35. Takeda Company Details
    Table 36. Takeda Business Overview
    Table 37. Takeda Retinal Biosimilars Product
    Table 38. Takeda Revenue in Retinal Biosimilars Business (2017-2022) & (US$ Million)
    Table 39. Takeda Recent Development
    Table 40. Bayer Company Details
    Table 41. Bayer Business Overview
    Table 42. Bayer Retinal Biosimilars Product
    Table 43. Bayer Revenue in Retinal Biosimilars Business (2017-2022) & (US$ Million)
    Table 44. Bayer Recent Development
    Table 45. Genentech Company Details
    Table 46. Genentech Business Overview
    Table 47. Genentech Retinal Biosimilars Product
    Table 48. Genentech Revenue in Retinal Biosimilars Business (2017-2022) & (US$ Million)
    Table 49. Genentech Recent Development
    Table 50. Pfenex Company Details
    Table 51. Pfenex Business Overview
    Table 52. Pfenex Retinal Biosimilars Product
    Table 53. Pfenex Revenue in Retinal Biosimilars Business (2017-2022) & (US$ Million)
    Table 54. Pfenex Recent Development
    Table 55. Reliance Life Sciences Company Details
    Table 56. Reliance Life Sciences Business Overview
    Table 57. Reliance Life Sciences Retinal Biosimilars Product
    Table 58. Reliance Life Sciences Revenue in Retinal Biosimilars Business (2017-2022) & (US$ Million)
    Table 59. Reliance Life Sciences Recent Development
    Table 60. Hetero Drugs Company Details
    Table 61. Hetero Drugs Business Overview
    Table 62. Hetero Drugs Retinal Biosimilars Product
    Table 63. Hetero Drugs Revenue in Retinal Biosimilars Business (2017-2022) & (US$ Million)
    Table 64. Hetero Drugs Recent Development
    Table 65. Intas Pharmaceuticals Company Details
    Table 66. Intas Pharmaceuticals Business Overview
    Table 67. Intas Pharmaceuticals Retinal Biosimilars Product
    Table 68. Intas Pharmaceuticals Revenue in Retinal Biosimilars Business (2017-2022) & (US$ Million)
    Table 69. Intas Pharmaceuticals Recent Development
    Table 70. Santo Holding Company Details
    Table 71. Santo Holding Business Overview
    Table 72. Santo Holding Retinal Biosimilars Product
    Table 73. Santo Holding Revenue in Retinal Biosimilars Business (2017-2022) & (US$ Million)
    Table 74. Santo Holding Recent Development
    Table 75. Regeneron Pharmaceuticals Company Details
    Table 76. Regeneron Pharmaceuticals Business Overview
    Table 77. Regeneron Pharmaceuticals Retinal Biosimilars Product
    Table 78. Regeneron Pharmaceuticals Revenue in Retinal Biosimilars Business (2017-2022) & (US$ Million)
    Table 79. Regeneron Pharmaceuticals Recent Development
    Table 80. Research Programs/Design for This Report
    Table 81. Key Data Information from Secondary Sources
    Table 82. Key Data Information from Primary Sources
List of Figures
    Figure 1. Retinal Biosimilars Product Picture
    Figure 2. Global Retinal Biosimilars Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Retinal Biosimilars Market Size 2017-2028 (US$ Million)
    Figure 4. United States Retinal Biosimilars Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Retinal Biosimilars Market Size 2017-2028 (US$ Million)
    Figure 6. United States Retinal Biosimilars Market Share in Global 2017-2028
    Figure 7. Retinal Biosimilars Report Years Considered
    Figure 8. Product Picture of Macular Degeneration Drugs
    Figure 9. Product Picture of Diabetic Eye Disease Drugs
    Figure 10. Product Picture of Macular Pucker Drugs
    Figure 11. Product Picture of Others
    Figure 12. Global Retinal Biosimilars Market Share by Type in 2022 & 2028
    Figure 13. Global Retinal Biosimilars Market Size by Type (2017-2028) & (US$ Million)
    Figure 14. Global Retinal Biosimilars Market Share by Type (2017-2028)
    Figure 15. United States Retinal Biosimilars Market Share by Type in 2022 & 2028
    Figure 16. United States Retinal Biosimilars Market Size by Type (2017-2028) & (US$ Million)
    Figure 17. United States Retinal Biosimilars Market Share by Type (2017-2028)
    Figure 18. Product Picture of Hospital Pharmacies
    Figure 19. Product Picture of Retail Pharmacies
    Figure 20. Product Picture of Online Pharmacies
    Figure 21. Global Retinal Biosimilars Market Share by Application in 2022 & 2028
    Figure 22. Global Retinal Biosimilars Market Size by Application (2017-2028) & (US$ Million)
    Figure 23. Global Retinal Biosimilars Market Share by Application (2017-2028)
    Figure 24. United States Retinal Biosimilars Market Share by Application in 2022 & 2028
    Figure 25. United States Retinal Biosimilars Market Size by Application (2017-2028) & (US$ Million)
    Figure 26. United States Retinal Biosimilars Market Share by Application (2017-2028)
    Figure 27. North America Retinal Biosimilars Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 28. U.S. Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 29. Canada Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 30. Europe Retinal Biosimilars Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 31. Germany Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. France Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. U.K. Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Italy Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Russia Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Asia-Pacific Retinal Biosimilars Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 37. China Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. Japan Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. South Korea Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. India Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Australia Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Taiwan Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Indonesia Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Thailand Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Malaysia Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Philippines Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Latin America Retinal Biosimilars Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 48. Mexico Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Brazil Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Argentina Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Middle East & Africa Retinal Biosimilars Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 52. Turkey Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Saudi Arabia Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. U.A.E Retinal Biosimilars Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Novartis (Sandoz) Revenue Growth Rate in Retinal Biosimilars Business (2017-2022)
    Figure 56. Takeda Revenue Growth Rate in Retinal Biosimilars Business (2017-2022)
    Figure 57. Bayer Revenue Growth Rate in Retinal Biosimilars Business (2017-2022)
    Figure 58. Genentech Revenue Growth Rate in Retinal Biosimilars Business (2017-2022)
    Figure 59. Pfenex Revenue Growth Rate in Retinal Biosimilars Business (2017-2022)
    Figure 60. Reliance Life Sciences Revenue Growth Rate in Retinal Biosimilars Business (2017-2022)
    Figure 61. Hetero Drugs Revenue Growth Rate in Retinal Biosimilars Business (2017-2022)
    Figure 62. Intas Pharmaceuticals Revenue Growth Rate in Retinal Biosimilars Business (2017-2022)
    Figure 63. Santo Holding Revenue Growth Rate in Retinal Biosimilars Business (2017-2022)
    Figure 64. Regeneron Pharmaceuticals Revenue Growth Rate in Retinal Biosimilars Business (2017-2022)
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Novartis (Sandoz)
Takeda
Bayer
Genentech
Pfenex
Reliance Life Sciences
Hetero Drugs
Intas Pharmaceuticals
Santo Holding
Regeneron Pharmaceuticals
Frequently Asked Questions
Retinal Biosimilars report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Retinal Biosimilars report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Retinal Biosimilars report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Waist Shaper

Waist Shaper market is segmented by region (country), players, by Type and by Application. Player ... Read More

Dimeric Fatty Acid

Dimeric Fatty Acid market is segmented by region (country), players, by Type and by Application.  ... Read More